/
DCF Valuation
Base-case fair value
$53.19
Intrinsic $70.92 · 25% MOS
Base-case summary
Our base-case DCF for CorMedix Inc. (CRMD) projects 10 years of free cash flow growth at 12.7% for years 1–5 and 6.4% for years 6–10, anchored to 12.7% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $195M in trailing free cash flow, this produces an intrinsic value of $70.92 per share. A 25% safety margin gives a fair value of $53.19.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$195M
Cash & equivalents
$178M
Total debt
$0
Shares outstanding
93M